Soligenix News

News

Ticker

SNGX

ISIN

US8342236044

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Soligenix Eulerpool News

Soligenix Stock News

Soligenix is being monitored by journalists and investors worldwide. We gather the latest Soligenix news here.

March 19·
Benzinga
Soligenix Says Summary Of All Clinical Trials Completed To Date Of Hybryte (Synthetic Hypericin) For Cutaneous T-Cell Lymphoma Has Been Published In The Peer-reviewed Medical Journal Expert Opinion On Investigational Drugs
March 12·
Benzinga
Watching Soligenix; Zacks Small-Cap Research Gives Stock $25.00 Price Valuation
March 10·
Benzinga
Soligenix's SGX945 (Dusquetide) Receives Promising Innovative Medicine Designation In U.K. For Behçet's Disease
February 26·
Yahoo
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
February 26·
Benzinga
Soligenix Says EMA COMP Issues Positive Opinion On Orphan Drug Designation Request For SGX945 Dusquetide In Behçet's Disease
February 24·
Yahoo
Soligenix to Present at BIO Investment & Growth Summit
February 12·
Yahoo
Soligenix Details Recent Progress and Upcoming Milestones
February 9·
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 18·
Benzinga
Soligenix Announces Results From Phase 2a Proof Of Concept Study Evaluating SGX945 In Treatment Of Behçet's Disease Published In Rheumatology (Oxford)
December 5·
Yahoo
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
December 3·
Yahoo
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
November 19·
Yahoo
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
November 19·
Benzinga
Soligenix Completes Planned Enrollment Of 50 Patients Necessary For Interim Analysis In 80 Patient Confirmatory Phase 3 Double-Blind, Placebo-Controlled Study Evaluating HyBryte In CTCL Treatment
November 7·
Benzinga
Soligenix Q3 EPS $(0.58) Misses $(0.56) Estimate
October 7·
Benzinga
Soligenix Reports No Safety Concerns In First DMC Review Of Phase 3 HyBryte Trial For CTCL
September 26·
Benzinga
Soligenix shares are trading lower after the company announced it priced its $7.5 million offering.
September 23·
Yahoo
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
September 23·
Benzinga
Soligenix shares are trading higher after the company appointed former White House economic adviser Tomas J. Philipson as a strategic advisor.
August 21·
Benzinga
5 Healthcare Stocks On Fire This Week
August 18·
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session

Soligenix Stock Press Releases

Soligenix regularly publishes news on the company's website that are relevant for investors.

November 15•
Soligenix
Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
November 11•
Soligenix
Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference
November 10•
Soligenix
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results
October 25•
Soligenix
Soligenix Announces Formation of Psoriasis Medical Advisory Board
October 20•
Soligenix
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
October 17•
Soligenix
New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
October 13•
Soligenix
Soligenix Enters Q4 With Multiple Catalysts in Play
September 23•
Soligenix
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
September 12•
Soligenix
FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL
September 8•
Soligenix
Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6•
Soligenix
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
August 12•
Soligenix
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
July 27•
Soligenix
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
July 26•
Soligenix
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients
July 25•
Soligenix
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
July 20•
Soligenix
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
June 28•
Soligenix
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
June 23•
Soligenix
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
June 7•
Soligenix
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis
June 1•
Soligenix
Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
May 23•
Soligenix
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
May 18•
Soligenix
Soligenix to Present at the H.C. Wainwright Global Investment Conference
May 13•
Soligenix
Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
April 19•
Soligenix
Soligenix Receives $1.4M in Non-Dilutive Government Funding
March 29•
Soligenix
Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results
March 17•
Soligenix
Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
March 2•
Soligenix
SG Blocks, Inc. Leads Round of Investment for Moliving, Inc.
March 2•
Soligenix
Soligenix to Present at the Q1 Virtual Investor Summit
March 1•
Soligenix
Soligenix, Inc. to Present at the Q1 Virtual Investor Summit
January 12•
Soligenix
Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)

Soligenix News 2026

This page contains all current news, analysis and press releases for Soligenix stock (SNGX, ISIN: US8342236044). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Soligenix.